Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 18/20 | 1.00 |
| ▸ | GRM3 | Q14832 | 18/20 | 1.00 |
| ▸ | GRM6 | O15303 | 3/20 | 1.00 |
| ▸ | GRM4 | Q14833 | 1/20 | 1.00 |
| ▸ | GRM8 | O00222 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24606225 | 1.00 | GRM2 (1.00) | GRM2GRM3GRM6GRM4GRM8 | |
| SCHEMBL6789617 | 1.00 | GRM2 (1.00) | GRM2GRM3GRM6GRM4GRM8 | |
| SCHEMBL6793703 | 0.87 | GRM2 (1.00) | GRM2GRM3GRM6GRM4GRM8 | |
| SCHEMBL6906939 | 0.87 | GRM2 (0.83) | GRM2GRM3GRM6GRM4GRM8 | |
| SCHEMBL6906931 | 0.87 | GRM2 (0.83) | GRM2GRM3GRM6GRM4GRM8 | |
| SCHEMBL6795693 | 0.86 | GRM2 (0.78) | GRM2GRM3GRM6GRM4GRM8 | |
| SCHEMBL6794351 | 0.85 | GRM2 (1.00) | GRM2GRM3GRM6GRM4GRM8 | |
| SCHEMBL6793748 | 0.84 | GRM2 (0.73) | GRM2GRM3GRM6GRM4GRM8 | |
| SCHEMBL6788367 | 0.84 | GRM2 (1.00) | GRM2GRM3GRM6GRM4GRM8 | |
| SCHEMBL7312412 | 0.84 | GRM2 (1.00) | GRM2GRM3GRM6GRM4GRM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220313650-A1 | METHODS FOR TREATING NEURODEVELOPMENTAL DISORDERS | THE BROAD INSTITUTE, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| US-20220211658-A1 | METHODS FOR TREATING DISORDERS ASSOCIATED WITH SLEEP SPINDLE DEFICITS | THE BROAD INSTITUTE, INC. (US) | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220313650-A1 | METHODS FOR TREATING NEURODEVELOPMENTAL DISORDERS | GRIN2A, GRIN2B, GRM2 | GRM2 3/4885GRM3 6/4885GRM6 19/4885 |
| US-20220211658-A1 | METHODS FOR TREATING DISORDERS ASSOCIATED WITH SLEEP SPINDLE DEFICITS | HCRTR2, GRIN2A, GRM2 | GRM2 3/4885GRM3 10/4885GRM6 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.